@article{MTMT:34818503, title = {A Rheopheresis kezelés komplex angiológiai hatásai}, url = {https://m2.mtmt.hu/api/publication/34818503}, author = {Gál, Kristóf and Németh, Norbert and Gálné Remenyik, Judit and Soltész, Pál}, journal-iso = {METABOLIZMUS}, journal = {METABOLIZMUS}, volume = {22}, unique-id = {34818503}, issn = {1589-7311}, year = {2024}, pages = {62-65}, orcid-numbers = {Németh, Norbert/0000-0002-1162-3778} } @article{MTMT:34693250, title = {Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus}, url = {https://m2.mtmt.hu/api/publication/34693250}, author = {Nagy, Nikolett and Bói, Bernadett and Papp, Gábor and Fiák, Edit and Gáspár-Kiss, Eszter and Perge, Bianka and Farmasi, Nikolett and Tarr, Tünde}, doi = {10.3390/biomedicines12030530}, journal-iso = {BIOMEDICINES}, journal = {BIOMEDICINES}, volume = {12}, unique-id = {34693250}, abstract = {In systemic lupus erythematosus (SLE), cardiovascular complications are among the leading causes of death. Cardiovascular risk in SLE is even higher in the presence of antiphospholipid antibodies or secondary antiphospholipid syndrome (APS). The aim of this retrospective, single-center study was to investigate the occurrence of antiphospholipid antibodies and non-thrombotic cardiac manifestations in 369 SLE patients. We also assessed the clinical and laboratory characteristics of the patients to reveal the risk factors for cardiac manifestations. Patients were divided into two groups based on the presence of antiphospholipid antibodies (APA); 258 (69.9%) patients were APA positive, and 111 (30.1%) patients were APA negative. Mitral and tricuspid insufficiency, aortic stenosis and pulmonary arterial hypertension were more common in APA-positive patients. Anticardiolipin IgG showed the strongest correlation with any non-thrombotic cardiac manifestations. Based on our results, the adjusted global antiphospholipid syndrome score (aGAPSS) above 8.5 is predictive of valvulopathies and ischemic heart disease, while aGAPSS above 9.5 is predictive of cardiomyopathies. The presence of antiphospholipid antibodies may affect the development of cardiac manifestations in SLE. Periodic cardiological and echocardiographic screening of patients without cardiac complaints, as well as regular monitoring of antiphospholipid antibodies, have great importance during the treatment of SLE patients.}, keywords = {antiphospholipid antibodies; systemic lupus erythematosus; aGAPSS; non-thrombotic cardiac manifestations}, year = {2024}, eissn = {2227-9059}, pages = {530} } @article{MTMT:33854100, title = {Pruritogenic molecules in the skin of patients with dermatomyositis}, url = {https://m2.mtmt.hu/api/publication/33854100}, author = {Vincze, Anett and Lisztes, Erika and Szabó, Katalin and Béldi, Tibor Gábor and Nagy-Vincze, Melinda and Pór, Ágnes and Varga, József and Dankó, Katalin and Bíró, Tamás and Tóth, Balázs István and Griger, Zoltán}, doi = {10.3389/fmed.2023.1168359}, journal-iso = {FRONT MED}, journal = {FRONTIERS IN MEDICINE}, volume = {10}, unique-id = {33854100}, abstract = {Introduction: Pruritus is a common excruciating symptom in systemic autoimmune diseases such as dermatomyositis (DM) but the pathogenesis is not fully understood. We intended to investigate the targeted expression analysis of candidate molecules involved in the development of pruritus in lesional vs. non-lesional skin samples of patients affected with active DM. We looked for correlations between the investigated pruriceptive signaling molecules, disease activity, and itching sensation of DM patients. Methods: Interleukins (IL-33 and IL-6), tumor necrosis factor α (TNF-α), peroxisome proliferator-activated receptor γ (PPAR-γ), and ion channels belonging to the transient receptor potential (TRP) family were analyzed. The expression of TNF-α, PPAR-γ, IL-33, IL-6, and TRP channels in lesional DM skin was evaluated by RT-qPCR and immunohistochemistry and was compared with non-lesional DM skin samples. Pruritus, disease activity, and damage of DM were evaluated by the 5-D itch scale and Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), respectively. Statistical analysis was performed with IBM SPSS 28 software. Results: A total of 17 active DM patients participated in the study. We could show that the itching score was positively correlated with the CDASI activity score (Kendall's tau-b = 0.571; p = 0.003). TNF-α gene expression was significantly higher in lesional DM skin than in non-lesional DM skin (p = 0.009) and differed in the subgroups of patients with different itch intensities (p = 0.038). The mRNA expression of lesional IL-6 correlated positively with 5-D itch and CDASI activity score (Kendall's tau-b = 0.585; p = 0.008 and 0.45; p = 0.013, respectively). TRPV4 expressions were positively correlated with CDASI damage score (Kendall's tau-b = 0.626; p < 0.001), but the mRNA expressions of the TRP family, PPAR-γ, IL-6, and IL-33 were not different in lesional and non-lesional samples. Immunohistochemistry analysis did not find significant alterations in the expressions of TNF-α, PPAR-γ, IL-6, and IL-33 in lesional and non-lesional regions. Discussion: Our results argue that cutaneous disease activity, TNF-α, and IL-6 might play a central role in DM-associated itch, while TRPV4 plays a central role in tissue regeneration.}, keywords = {pruritus; dermatomyositis; IL-6; TRP CHANNELS; INFLAMMATORY MYOPATHIES; Itch; TNF-α = tumor necrosis factor α}, year = {2023}, eissn = {2296-858X} } @article{MTMT:33779293, title = {Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and 2 surveys}, url = {https://m2.mtmt.hu/api/publication/33779293}, author = {Naveen, R. and Sen, Parikshit and Griger, Zoltán and Day, Jessica and Joshi, Mrudula and Nune, Arvind and Nikiphorou, Elena and Saha, Sreoshy and Tan, Ai Lyn and Shinjo, Samuel Katsuyuki and Ziade, Nelly and Velikova, Tsvetelina and Milchert, Marcin and Jagtap, Kshitij and Parodis, Ioannis and Gracia-Ramos, Abraham Edgar and Cavagna, Lorenzo and Kuwana, Masataka and Knitza, Johannes and Chen, Yi Ming and Makol, Ashima and Agarwal, Vishwesh and Patel, Aarat and Pauling, John D. and Wincup, Chris and Barman, Bhupen and Zamora, Tehozol Erick Adrian and Serrano, Jorge Rojas and García-De, La Torre Ignacio and Colunga-Pedraza, Iris J. and Merayo-Chalico, Javier and Chibuzo, Okwara Celestine and Katchamart, Wanruchada and Goo, Phonpen Akawatcharangura and Shumnalieva, Russka and Hoff, Leonardo Santos and El, Kibbi Lina and Halabi, Hussein and Vaidya, Binit and Shaharir, Syahrul Sazliyana and Hasan, A. T. M. Tanveer and Dey, Dzifa and Gutiérrez, Carlos-Enrique Toro and Caballero-Uribe, Carlo Vinicio and Lilleker, James B. and Salim, Babur and Gheita, Tamer A. and Chatterjee, Tulika and Distler, Oliver and Saavedra, Miguel A. and Chinoy, Hector and Agarwal, Vikas and Aggarwal, Rohit and Gupta, Latika}, doi = {10.1093/rheumatology/kead180}, journal-iso = {RHEUMATOLOGY}, journal = {RHEUMATOLOGY (UNITED KINGDOM)}, volume = {[Epub ahead of print]}, unique-id = {33779293}, issn = {1462-0324}, abstract = {Objectives: Disease flares in the post COVID-19 vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods: The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022 respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history, and vaccination details.Flares of IIMs were defined as a. patient self-reported, b. immunosuppression (IS) denoted, c. clinical sign directed, and d. with >7.9-point MCID worsening of PROMISPF10a score. Risk factors of flares were analyzed using regression models. Results: Of 15165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians), and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7%, and 19.6% patients by definitions a-d respectively with a median time to flare of 71.5 (10.7-235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR:1.2; 95%CI:1.03-1.6, p = 0.025) were prone to flares, while those receiving Rituximab (OR:0.3; 95%CI:0.1-0.7, p = 0.010) and Azathioprine (OR:0.3, 95%CI:0.1-0.8, p = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in immunosuppression. Asthma (OR: 1.62; 95%CI: 1.05-2.50, p = 0.028) and higher pain VAS (OR: 1.19; 95%CI: 1.11-1.27, p < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion: A diagnosis of IIMs confers an equal risk of flares in the post COVID-19 vaccination period to AIRDs, with active disease, female gender, and comorbidities conferring a higher risk. Disparity between patient and physician reported outcomes represents a future avenue for exploration.}, keywords = {disease exacerbation; IDIOPATHIC INFLAMMATORY MYOPATHIES; Patient reported outcomes; COVID-19 Vaccines}, year = {2023}, eissn = {1462-0332} } @article{MTMT:33777179, title = {Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades}, url = {https://m2.mtmt.hu/api/publication/33777179}, author = {Nagy, Nikolett and Papp, Gábor and Gáspár-Kiss, Eszter and Diószegi, Ágnes and Tarr, Tünde}, doi = {10.3390/biomedicines11041218}, journal-iso = {BIOMEDICINES}, journal = {BIOMEDICINES}, volume = {11}, unique-id = {33777179}, abstract = {Systemic lupus erythematosus (SLE) is often associated with antiphospholipid syndrome (APS), which potentially results in a more severe disease course and reduced life expectancy. Since the therapeutic guidelines have been refined in the last 15 years, we assumed that the diseases course has become more favorable. In order to shed light on these achievements, we compared the data of SLE patients diagnosed before and since 2004. In our retrospective study, we assessed a wide spectrum of clinical and laboratory data of 554 SLE patients who received regular follow-up care and therapy at our autoimmune center. Among these patients, 247 had antiphospholipid antibodies (APAs) without clinical signs of APS, and 113 had definitive APS. In the APS group, among patients diagnosed since 2004, deep vein thrombosis (p = 0.049) and lupus anticoagulant positivity (p = 0.045) were more frequent, while acute myocardial infarction was less frequent (p = 0.021) compared with patients diagnosed before 2004. Among the APA positive patients without definitive APS, anti-cardiolipin antibody positivity (p = 0.024) and development of chronic renal failure (p = 0.005) decreased in patients diagnosed since 2004. Our study demonstrates that the disease course has changed in recent years; however, in the presence of APS, we have to expect repeated thrombotic events despite adequate anticoagulant therapy.}, keywords = {Therapy; disease course; systemic lupus erythematosus; ANTIPHOSPHOLIPID SYNDROME}, year = {2023}, eissn = {2227-9059}, pages = {1-10} } @article{MTMT:33692161, title = {Contrasting Autoimmune Comorbidities in Microscopic Colitis and Inflammatory Bowel Diseases}, url = {https://m2.mtmt.hu/api/publication/33692161}, author = {Fedor, István and Zöld, Éva and Barta, Zsolt}, doi = {10.3390/life13030652}, journal-iso = {LIFE-BASEL}, journal = {LIFE-BASEL}, volume = {13}, unique-id = {33692161}, abstract = {Background: Inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and microscopic colitis (lymphocytic and collagenous colitis) are immune-mediated diseases of the gastrointestinal tract, with distinct pathophysiology. Objective: We sought to compare the prevalence of autoimmune diseases between microscopic colitis (MC) and inflammatory bowel diseases (IBDs) in our patient cohorts in their medical history. Methods: We collected data from 611 patients (508 with IBD, 103 with MC). We recorded cases of other autoimmune diseases. The screened documentation was written in the period between 2008 and 2022. We sought to determine whether colonic involvement had an impact on the prevalence of autoimmune diseases. Results: Ulcerative colitis patients and patients with colonic-predominant Crohn’s disease had a greater propensity for autoimmune conditions across the disease course than patients with ileal-predominant Crohn’s disease. Gluten-related disorders were more common in Crohn’s disease than in ulcerative colitis, and slightly more common than in microscopic colitis. In ulcerative colitis, 10 patients had non-differentiated collagenosis registered, which can later develop into a definite autoimmune disease. Conclusions: Predominantly colonic involvement can be a predisposing factor for developing additional autoimmune disorders in IBD. Ulcerative colitis patients may have laboratory markers of autoimmunity, without fulfilling the diagnostic criteria for definitive autoimmune disorders (non-differentiated collagenosis).}, year = {2023}, eissn = {2075-1729}, orcid-numbers = {Barta, Zsolt/0000-0002-8200-6937} } @article{MTMT:33688871, title = {Role of Altered Metabolism of Triglyceride-Rich Lipoprotein Particles in the Development of Vascular Dysfunction in Systemic Lupus Erythematosus}, url = {https://m2.mtmt.hu/api/publication/33688871}, author = {Diószegi, Ágnes and Lőrincz, Hajnalka and Kaáli, Eszter and Soltész, Pál and Perge, Bianka and Varga, Éva and Harangi, Mariann and Tarr, Tünde}, doi = {10.3390/biom13030401}, journal-iso = {BIOMOLECULES}, journal = {BIOMOLECULES}, volume = {13}, unique-id = {33688871}, issn = {2218-273X}, abstract = {Background: Impaired lipid metabolism contributes to accelerated inflammatory responses in addition to promoting the formation of atherosclerosis in systemic lupus erythematosus (SLE). We aimed to evaluate the lipid profile, inflammatory markers, and vascular diagnostic tests in active SLE patients to clarify the association between dyslipidemia and early vascular damage. Patients and Methods: 51 clinically active SLE patients and 41 age- and gender-matched control subjects were enrolled in the study. Lipoprotein subfractions were detected by Lipoprint. Brachial artery flow-mediated dilation and common carotid intima-media thickness were detected by ultrasonography. Arterial stiffness indicated by augmentation index (Aix) and pulse wave velocity was measured by arteriography. Results: We found significantly higher Aix, higher VLDL ratio, plasma triglyceride, ApoB100, and small HDL, as well as lower HDL-C, large HDL, and ApoA1 in patients with SLE. There was a significant positive correlation of Aix with triglyceride, VLDL, IDL-C, IDL-B, and LDL1. A backward stepwise multiple regression analysis showed IDL-C subfraction to be the best predictor of Aix. Conclusions: Our results indicate that in young patients with SLE, triglyceride-rich lipoproteins influence vascular function detected by Aix. These parameters may be assessed and integrated into the management plan for screening cardiovascular risk in patients with SLE.}, year = {2023}, eissn = {2218-273X}, orcid-numbers = {Varga, Éva/0000-0003-2716-0541} } @article{MTMT:33687603, title = {Novel aspects of muscle involvement in immune-mediated inflammatory arthropathies and connective tissue diseases}, url = {https://m2.mtmt.hu/api/publication/33687603}, author = {Mogyoróssy, Sándor Lajos and Nagy-Vincze, Melinda and Griger, Zoltán and Dankó, Katalin and Szabó, Nóra Anna and Szekanecz, Zoltán and Szűcs, Gabriella and Szántó, Antónia and Bodoki, Levente}, doi = {10.1016/j.autrev.2023.103311}, journal-iso = {AUTOIMMUN REV}, journal = {AUTOIMMUNITY REVIEWS}, volume = {22}, unique-id = {33687603}, issn = {1568-9972}, abstract = {Myalgia, myopathy and myositis are the most important types of muscle impairment in immune-mediated inflammatory arthropathies and connective tissue diseases. Multiple pathogenetic and histological changes occur in the striated muscles of these patients. Clinically, the most important muscle involvement is the one that causes complaints to the patients. In everyday practice, insidious symptoms present a serious problem for the clinician; in many cases, it is difficult to decide when and how to treat the muscle symptoms that are often present only subclinically. In this work, authors review the international literature on the types of muscle problems in autoimmune diseases. In scleroderma histopathological picture of muscle shows a very heterogeneous picture, necrosis and atrophy are common. In rheumatoid arthritis and systemic lupus erythematosus, myopathy is a much less defined concept, further studies are needed to describe it. According to our view, overlap myositis should be recognized as a separate entity, preferably with distinct histological and serological characteristics. More studies are needed to describe muscle impairment in autoimmune diseases which may help to explore this topic more in depth and be of clinical use.}, year = {2023}, eissn = {1873-0183} } @article{MTMT:33687590, title = {Incidence, features and outcome of disease relapse after COVID ‐19 vaccination in patients with idiopathic inflammatory myopathies}, url = {https://m2.mtmt.hu/api/publication/33687590}, author = {Nagy-Vincze, Melinda and Béldi, Tibor and Szabó, Katalin and Vincze, Anett and Miltényi‐Szabó, Balázs and Varga, Zsófia and Varga, József and Griger, Zoltán}, doi = {10.1002/mus.27811}, journal-iso = {MUSCLE NERVE}, journal = {MUSCLE & NERVE}, volume = {67}, unique-id = {33687590}, issn = {0148-639X}, abstract = {Introduction/Aims: Vaccination against coronavirus disease 2019 (COVID-19) is relatively safe in patients with idiopathic inflammatory myopathies (IIM); however, myositis flares following vaccination have been poorly studied. We aimed to evaluate the frequency, features, and outcomes of disease relapses in patients with IIM following COVID-19 vaccination. Methods: A cohort of 176 IIM patients were interviewed after the third wave of the COVID-19 pandemic and followed prospectively. Relapses were determined using the disease state criteria and the outcome of the flares with myositis response criteria, calculating the total improvement score (TIS). Results: A total of 146 (82.9%) patients received a vaccination, 17/146 (11.6%) patients had a relapse within 3 mo, and 13/146 (8.9%) patients within 1 mo. The relapse rate of unvaccinated patients was 3.3%. Three months after the post-vaccination relapses, 70.6% of the patients (12/17) achieved an improvement of disease activity (average TIS score: 30 ± 15.81; seven minor, five moderate, and zero major improvements). Six months after flares improvement was detected in 15/17(88.2%) of relapsed patients (average TIS score: 43.1 ± 19.53; 3 minimal, 8 moderate, and 4 major). Forward stepwise logistic regression analysis revealed that the active state of myositis at the time of injection (p <.0001; odds ratio, 33; confidence interval, 9–120) was significantly associated with the occurrence of a relapse. Discussion: A minority of the vaccinated IIM patients had a confirmed disease flare after COVID-19 vaccination and the majority of the relapses improved after individualized treatment. An active disease state at the time of vaccination probably contributes to the increased risk of a post vaccination myositis flare.}, year = {2023}, eissn = {1097-4598}, pages = {371-377}, orcid-numbers = {Varga, József/0000-0001-5797-9625} } @article{MTMT:33134965, title = {The effect of COVID-19 pandemic on idiopathic inflammatory myositis patients: a single centre experience}, url = {https://m2.mtmt.hu/api/publication/33134965}, author = {Béldi, Tibor and Vincze, Anett and Miltényi-Szabó, Balázs and Varga, Zsófia and Szabó, Katalin and Griger, Zoltán and Nagy-Vincze, Melinda}, doi = {10.55563/clinexprheumatol/eisexh}, journal-iso = {CLIN EXP RHEUMATOL}, journal = {CLINICAL AND EXPERIMENTAL RHEUMATOLOGY}, volume = {41}, unique-id = {33134965}, issn = {0392-856X}, abstract = {Objective Pandemic caused by coronavirus disease (COVID-19) determines the life of clinicians and patients since 2 years. We have a lot of information about disease course, treatment and protection against virus, but less on the prognosis of infection in patients with idiopathic inflammatory myopathies (IIM). Also few data are available on triggered humoral response and side effects after vaccination. Methods Our goal was to assess by a retrospective cross-sectional study the above data in our cohort (176 IIM patients) by identifying COVID-19 positive patients and follow disease course. Incidence and complications of vaccination were determined by questionnaires. 101 patients volunteered for complex blood test. Results By June 1st, 2021 significantly higher incidence of COVID 19 infections (34.7%) were identified comparing to the national prevalence (8.2%). A third of these infections occurred asymptomatically or mild. Patients requiring hospitalisation had a significantly longer disease duration and a higher incidence of anti-Jo-1 antibody. All patients infected by COVID-19 became seropositive regardless the immunosuppressive therapy or symptoms severity. 54.3% of the patients received anti-COVID-19 vaccine. 72.3% of patients became seropositive after vaccination. Higher antibody titre against spike protein was detected after Pfizer-BioNTech vaccination compared to others. Patients receiving steroid therapy had decreased post-vaccination antibody response compared to those without steroid treatment. No major post-vaccination infection was observed Conclusion Based on our results, myositis may be associated with an increased risk of COVID-19 infection. Independent risk factor for hospitalisation are longer disease duration and anti-Jo1 positivity. Anti-SARS-CoV2 vaccines seem safe and tolerable and strongly recommended for that population.}, year = {2023}, eissn = {1593-098X}, pages = {254-260} }